Two-year outcomes of epicranial focal cortex stimulation in pharmacoresistant focal epilepsy.

ABSTRACT:

Objective

This study was undertaken to report on the long-term safety and efficacy of epicranial focal cortex stimulation (FCS) using the EASEE device as adjunctive neuromodulatory therapy in improving seizure control in adults with pharmacoresistant epilepsy originating from one predominant epileptogenic zone.

Methods

Prospective open-label follow-up of patients from the EASEE II and PIMIDES I clinical trials was done for a period of 2 years after the epicranial implantation of the EASEE electrode and stimulator device.

Results

Thirty-three patients underwent device implantation, and stimulation was activated in 32 patients. Of these, 26 patients continued stimulation up to 2-year follow-up and provided seizure diary data for efficacy analysis. The 50% responder rate

SUBMITTER: Schulze-Bonhage A 

PROVIDER: S-EPMC12455469 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature